Allotera Therapeutics
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
$35MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers
Pitching Blood Cancer United's Therapy Acceleration Program? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room